Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Control of cytokine mRNA degradation by the histone deacetylase inhibitor ITF2357 in rheumatoid arthritis fibroblast-like synoviocytes: beyond transcriptional regulation

Fig. 2

ITF2357 accelerates the mRNA decay of inflammatory markers. a Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) (n = 6) were left untreated or were treated with ITF2357 prior to incubation with IL-1β for 2 h. Transcription was blocked with actinomycin D (ActD) and RNA extracted at the indicated time points. Graphs show representative genes with enhanced mRNA degradation in the presence of ITF2357 (top panel), and examples of genes that were not regulated by ITF2357 at the level of transcript stability (bottom panel): *p < 0.05, Wilcoxon matched pairs test. b RA FLS (n = 7) were left untreated or were treated with ITF2357 prior to incubation with IL-1β for 4 and 8 h. The expression of primary transcripts (PT) and mature transcripts of IL6, IL8, PTGS2 and MMP1 were assessed by qPCR. Results are presented as 2^(-ΔCT) of the targets of interest normalized to GAPDH housekeeping gene. Percentages indicate the average suppression caused by the presence of ITF2357 in the 7 independent experiments: *p < 0.05, **p < 0.01, ***p < 0.001, one-way analysis of variance with Greenhouse-Geisser correction followed by Fisher’s least significant difference test

Back to article page